A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)
This is a Phase Ⅰ/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and above Myelodysplastic Syndrome (MDS) Patients after Failure of Hypomethylating Agent (HMA)-based Therapy.
Myelodysplastic Syndrome
DRUG: ATG-016
MTD in Phase I, MTD will be evaluated using the NCI-CTCAE, Version 5.0, 16 months|RP2D in Phase I, RP2D will be determined under the guidance of the SRC., 16 months|AEs/SAEs, Toxicity will be graded according to the NCI CTCAE, Version 5.0., 25 months|ORR in Phase II, Based on 2006 IWG Response Criteria, evaluated by IRC: ORR (CR + PR + mCR), 25 months
Disease Control Rate (DCR) in Phase I/II, DCR (CR + PR + mCR + HI + SD), 12 months|Duration of Response (DOR) in Phase I/II, To evaluate duration of response, 12 months|Progression-Free Survival (PFS) in Phase I/II, To evaluate progression-free survival, 12 months|Overall Survival (OS), The estimates of Kaplan-Meier, 12 months
This is a Phase Ⅰ/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and above Myelodysplastic Syndrome (MDS) Patients after Failure of Hypomethylating Agent (HMA)-based Therapy. In Phase I: approximately 15 to 21 subjects and Phase II: approximately 44 subjects; approximately 59 to 65 subjects will be enrolled totally in this study.